MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
First received: September 13, 2012
Last updated: April 25, 2013
Last verified: April 2013
This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab administered subcutaneously (SC) in addition to standard of care in subjects who participated in the MEA112997 study. At each clinic visit, adverse events will be assessed and exacerbations will also be reviewed.
||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial
Primary Outcome Measures:
- Frequency of all Adverse Events [ Time Frame: 48 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- ECG parameters [ Time Frame: 48 months ] [ Designated as safety issue: No ]
ECG parameters as measured by mean change and maximum change from baseline in QTcF and QT
- Clinical laboratory tests [ Time Frame: 48 months ] [ Designated as safety issue: No ]
Clinical laboratory tests as measured by abnormal parameters for hematology and clinical chemistry
- Vital Signs [ Time Frame: 48 months ] [ Designated as safety issue: No ]
Vital signs as measured by change in pulse and BP from baseline
- Annualized rate of exacerbation [ Time Frame: 48 months ] [ Designated as safety issue: No ]
- Quality of Life (QOL) [ Time Frame: 48 months ] [ Designated as safety issue: No ]
QOL as measured by Asthma Control Questionnaire score (ACQ)-5
- Lung Function [ Time Frame: 48 months ] [ Designated as safety issue: No ]
Lung function as measured by changes from baseline in Forced vital capacity (FVC) and Forced expiratory volume in 1 second (FEV1) measured by clinic spirometry
- Immunogenecity [ Time Frame: 48 months ] [ Designated as safety issue: No ]
Immunogenecity as measured by positive neutralizing antibody
- Number of participant withdrawals [ Time Frame: 48 months ] [ Designated as safety issue: No ]
Number of participant withdrawals due to lack of efficacy or due to adverse events were summarized
- Number of hospitalizations due to adverse events including asthma exacerbations [ Time Frame: 48 months ] [ Designated as safety issue: No ]
- Frequency of immune reactions [ Time Frame: 48 months ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||June 2016 (Final data collection date for primary outcome measure)
Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.
100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Informed Consent.
- MEA112997 Study Participation: Received at least 2 doses of double-blind investigational product during the MEA112997 trial.
- MEA112997 Treatment Assignment: If the subject received mepolizumab, they must have had a positive risk: benefit ratio.
- Currently being treated with a controller medication and the subject has been on a controller medication for the past 12 weeks.
- Male or Eligible Female Subjects. To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control for the duration of the trial and for 4 months after the last study drug administration.
- Hypersensitivity related to mepolizumab.
- Clinically significant change in health status since completing participation in the MEA112997 trial.
- A current malignancy or previous history of cancer in remission for less than 12 months prior to screening.
- For those subjects who had a SAE in MEA112997 that was assessed as possibly related to mepolizumab by the investigator.
- Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation.
- Screening ECG which has a clinically significant abnormality.
- Received Xolair (omalizumab) within the past 130 days.
- Participated in a clinical trial within the past 30 days or have received investigational medication within five terminal half-lives of Screen Visit, whichever is longer.
- Current smokers.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01691859
||GSK Clinical Trials
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 13, 2012
||April 25, 2013
||Ukraine: Ministry of Health of Ukraine, State Expert Center (SEC) of the Ministry of Health of Ukraine
Romania: Agentia Nationala a Medicamentului
Chile:Ministerio de Salud de Chile
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Poland: URZAD REJESTRACJI PRODUKTOW LECZNICZYCH, WYROBOW MEDYCZNYCH I PRODUKTOW BIOBOJCZYCH
United States: Food and Drug Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Russia: Russian Ministry of Health
Canada: Health Canada
Korea: Korea Food & Drug Administration
Germany: Bundesinstitut für Arzneimittel und Medizinprodukte
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Australia: Therapeutic Goods Administration
Keywords provided by GlaxoSmithKline:
Severe refractory asthma
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 19, 2013
Respiratory Tract Diseases
Lung Diseases, Obstructive
Immune System Diseases